Blood test strategy tested to time lung cancer treatment switch
NCT ID NCT02856893
Summary
This study aimed to find the best timing for using a newer lung cancer drug called osimertinib in patients with a specific genetic change (EGFR mutation). It compared starting the drug right away versus starting an older drug first and then switching to osimertinib later, guided by either standard scans or a special blood test. The trial also tested if these blood tests (liquid biopsies) could reliably detect cancer progression and predict which patients would benefit from switching drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Assistance Publique - Hopitaux de Marseille - Hopital Nord
Marseille, France
-
CHU Toulouse - Hopital Larrey
Toulouse, France
-
CHU de Brest
Brest, France
-
Centre Francois Baclesse
Caen, France
-
Centre Hopitalier Intercommunal De Creteil
Créteil, France
-
Centre Paul Strauss
Strasbourg, France
-
Gustave Roussy
Villejuif, France
-
Hospital Clinic Universitari de Barcelona
Barcelona, Spain
-
Hospital De La Santa Creu I Sant Pau
Barcelona, Spain
-
Hospital Universitario 12 De Octubre
Madrid, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, Spain
-
Institut Bergonie
Bordeaux, France
-
Institut Catala d'Oncologia - ICO Badalona - Hospital De Mataro
Mataró, Spain
-
Institut Jules Bordet
Brussels, Bruxelles Région, 1070, Belgium
-
Institut Paoli-Calmettes
Marseille, France
-
Institut de Cancerologie de Lorraine
Vandœuvre-lès-Nancy, France
-
King Hussein Cancer Center
Amman, Jordan
-
Medical University of Gdansk
Gdansk, Poland
-
The Institute Of Oncology
Ljubljana, Slovenia
-
University Clinic Golnik
Golnik, Slovenia
-
University Hospital A Coruna-Hospital Teresa Herrera
A Coruña, Spain
-
Vall d'Hebron Institut d'Oncologia
Barcelona, Spain
-
Virgen del Rocio University Hospital
Seville, Spain
Conditions
Explore the condition pages connected to this study.